Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
About INA-RESPOND: The Indonesian Research Partnership on Infectious Disease (INA-RESPOND) stands at the forefront of infectious disease research. Our esteemed network comprises professionals driven to make meaningful contributions to the global understanding of communicable diseases. We promote innovative solutions and approaches in the battle against infectious diseases by forging cooperation with premier universities and researchers
By: Aly Diana The integration of data-sharing practices in health research marks a pivotal advancement in scientific discovery and public health. This shift towards open science is revolutionizing how we approach medical research, yielding profound benefits for society as a whole. Maximizing Utility of Research Data The primary advantage of data sharing lies in maximizing
By: Erni, Adhella Menur Breathing is a vital right for every living creature, and good air quality is essential for environmental survival and sustainability. Concerns over air pollution levels continue to grow, as over 95% of the world’s population breathes polluted air. Air pollution is described as a ‘silent public health emergency’ and ‘the new
By: Aly Diana The American Society of Tropical Medicine and Hygiene (ASTMH) Conference was held at the Hy-att Regency Chicago in Illinois, USA, from October 18 to 22, 2023. This bustling event hosted 13 simultaneous sessions and attracted approximately 4,300 participants from over 130 countries. The conference covered a broad spectrum of topics, including mosquito-borne
By: Adhella Menur, Melinda Setiyaningrum Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), was the deadliest infectious disease until COVID-19 surpassed it in 2020. The COVID-19 pandemic disrupted the positive global trend of TB control, setting it back by roughly ten years. With the waning of the COVID-19 emergency and the rising incidence and death toll
To collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
